ResearcherKochi Health Sciences CenterNo recent work listed
Yasuhiro Shimada
Matched on ORCID iD 0000-0003-1385-696X; OpenAlex author ID A5101787797. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 14
2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 6
- Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. Co-author DOI 10.3390/jcm11226792↗
- A proposal to modify the 8th edition of the UICC staging system for pancreatic adenocarcinoma. Last author DOI 10.1007/s00423-021-02167-z↗
- Preoperative neutrophili-to-lymphocyte ratio is useful for stratifying the prognosis of tumor markers-negative pancreatic cancer patients. Last author DOI 10.1016/j.amjsurg.2019.04.014↗
- FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. Co-author DOI 10.1124/jpet.118.248740↗
- A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6485-7↗
- Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer. Last author DOI 10.1259/bjr.20170165↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jun Iwata · 5 shared papers, 2017–2022 · strength 0.56
- Paper Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. DOI 10.3390/jcm11226792↗
- Paper Preoperative neutrophili-to-lymphocyte ratio is useful for stratifying the prognosis of tumor markers-negative pancreat… DOI 10.1016/j.amjsurg.2019.04.014↗
- Paper A proposal to modify the 8th edition of the UICC staging system for pancreatic adenocarcinoma. DOI 10.1007/s00423-021-02167-z↗
- Takehiro Okabayashi MD · 5 shared papers, 2017–2022 · strength 0.56
- Paper Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. DOI 10.3390/jcm11226792↗
- Paper Preoperative neutrophili-to-lymphocyte ratio is useful for stratifying the prognosis of tumor markers-negative pancreat… DOI 10.1016/j.amjsurg.2019.04.014↗
- Paper A proposal to modify the 8th edition of the UICC staging system for pancreatic adenocarcinoma. DOI 10.1007/s00423-021-02167-z↗
- Kenta Sui · 5 shared papers, 2017–2022 · strength 0.56
- Paper Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. DOI 10.3390/jcm11226792↗
- Paper Preoperative neutrophili-to-lymphocyte ratio is useful for stratifying the prognosis of tumor markers-negative pancreat… DOI 10.1016/j.amjsurg.2019.04.014↗
- Paper A proposal to modify the 8th edition of the UICC staging system for pancreatic adenocarcinoma. DOI 10.1007/s00423-021-02167-z↗
- Tatsuo Iiyama · 4 shared papers, 2017–2022 · strength 0.43
- Paper Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. DOI 10.3390/jcm11226792↗
- Paper A proposal to modify the 8th edition of the UICC staging system for pancreatic adenocarcinoma. DOI 10.1007/s00423-021-02167-z↗
- Paper A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer. DOI 10.1245/s10434-018-6485-7↗
- Takatsugu Matsumoto · 2 shared papers, 2020–2021 · strength 0.27
- Yasuo Shima · 2 shared papers, 2017–2018 · strength 0.15
- Tatsuaki Sumiyoshi · 2 shared papers, 2017–2018 · strength 0.15
- Toshiyoshi Fujiwara · 1 shared paper, 2022 · strength 0.15
- Keiichi Kubota · 1 shared paper, 2021 · strength 0.13
- Shinji Mima · 1 shared paper, 2018 · strength 0.07
- H. Iwamura · 1 shared paper, 2018 · strength 0.07
- Tamami Higuchi · 1 shared paper, 2018 · strength 0.07
- Akihito Nishioka · 1 shared paper, 2017 · strength 0.06
- Manabu Matsumoto · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.